1. Home
  2. Medical treatment
  3. Medical centers & clinical studies
  4. Clinical studies and medical documentation
  5. Internal Medicine - CARAT

Information sheet on the clinical trial - CARAT

Main indication

Renal cell carcinoma and urothelial/bladder carcinoma

 

Study name (study type)

CARAT (registry platform)

 

Study sponsor

IOMEDICO

 

Registration number

ClinicalTrials.gov Identifier: NCT03374267

 

FOR RUSH READERS:

Study for patients with advanced and inoperable or metastatic renal cell carcinoma (RCC) as well as with advanced and inoperable or metastatic urothelial/bladder cancer (UBC). Treatment data, questionnaires, and tissue samples from the patients’ tumors will be collected for future research projects. This is an observational study and has no influence on the treatment method prescribed by the doctor.

 

DETAILED INFORMATION

The aim of this study is to document treatment practices, with a particular focus on their evolution over the years, as well as to describe the factors leading to treatment decisions and to analyze and evaluate the effectiveness of therapies and the associated assessment of health-related quality of life. 

 

Study Title

CARAT Urological Tumors Registry Platform

 

Which diseases are treated within the study?

Renal cell carcinoma (RCC)

Urothelial/bladder cancer (UBC)

 

Are specific subgroups of patients with any of the aforementioned conditions being treated?

No

 

Background on the study medication

None

 

Study Protocol.

Patients are asked to complete a questionnaire before the start of first-line treatment and then every 3 months for a maximum of 2 years, as well as to give their consent to the release of routinely collected tissue samples for future research projects.

 

Inclusion criteria

  • Patients with renal cell carcinoma or urothelial/bladder cancer requiring treatment (local, advanced, inoperable, or metastatic)
  • Patients at the start of their first-line systemic treatment 
  • Patients who are 18 years of age or older

 

Exclusion criteria

  • Patients who have received prior systemic therapy 
  • No systemic therapy  
  • The patient is simultaneously participating in a clinical trial and receiving active treatment

 

Your contacts: Investigators at the center and contact information

Dr. Guido Platz

Email: platz@~@gp-ruesselsheim.de

 

Responsible staff members in the study clinic

Heike Borchert (Study Coordinator)

Email: borchert@~@gp-ruesselsheim.de

Phone: 06142 88-1032

Clinical studies and medical documentation